Navigation Links
Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
Date:12/1/2008

COPENHAGEN, December 1 /PRNewswire/ -- A strong pipeline makes the Copenhagen Region biotech cluster well prepared for the challenges ahead. With 185 drug candidates in preclinical and clinical development, Denmark ranks third in Europe. Only United Kingdom and Germany have a bigger pipeline.

Also in term of pipeline growth Denmark has a strong position as it experienced the largest pipeline growth among the countries in Europe.

These are the two main findings of the Ernst & Young report "Biotech in Denmark 2008 - Growing stronger" prepared in cooperation with the Danish Association of Biotechnology Industries.

"Being a global biotech company founded in Denmark, Genmab is proud to be part of the important Medicon Valley biotech sector. We have found the innovative climate inspiring in the process of building our late stage pipeline," says Lisa N. Drakeman, Ph. D., Chief Executive Officer of Genmab.

The report underlines the role of the Copenhagen Region. Of the 82 biotech companies in Denmark, 74 per cent are located in the Danish part of Medicon Valley, a biotech cluster stretching across the Copenhagen region and the south of Sweden.

The strong pipeline is backed by a proven ability to take drug candidates into preclinical and clinical development. Despite general difficulties in the western economies, many new companies have been founded over the latest years. The richness in young companies with a number of potential drug candidates in their pipeline opens a wide range of business opportunities for international companies willing to engage in partnerships.

"It is a great pleasure to see the Danish biotech environment keeping up its level. Denmark has a variety of smaller as well as bigger companies within biotech, ensuring ongoing innovation. The stronghold of the region was one of the reasons why Genzyme chose Copenhagen for our Nordic headquarters. We have already benefited from this location as in 2005 we bought a local biotech company, which is now Genzyme Biosurgery, producing cartilage for surgery purposes," says Hilde Furberg, Vice President for Genzyme's Northern Region in Europe.

A breakdown of the key indication area for the Danish compounds currently in clinical trials reveals that oncology is by far the largest with 37 per cent. Out of the 260 cancer compounds in clinical development in Europe, Denmark accounts for 17 per cent of the European pipeline.

Neurology (15 per cent) and inflammation/autoimmune diseases (14 per cent) are the fields with second and third most Danish compounds in clinical trials.

"The broad variety of competences has helped the Copenhagen Region position itself as one of the absolute top biotech clusters in Europe through a number of years. Besides the strong pipeline I notice that Denmark is in the European top five when it comes to the ability to attract venture capital," says Steen Donner, Managing Director of Copenhagen Capacity.

The Ernst & Young report "Biotech in Denmark 2008 - Growing stronger" can be downloaded at:

http://www.copcap.com/reports

For further information and comments please contact: Christina Heje, Business Development Manager, Copenhagen Capacity. Mobile: +45-28-94-13-41. Mail: che@copcap.com


'/>"/>
SOURCE Copenhagen Capacity
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area
2. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Youngs experiment in a hydrogen molecule
5. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
6. Genome Technology Magazine Names Top Young Investigators of 2007
7. The neural basis of number sense in young infants
8. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
9. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
10. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
11. Agent in red wine found to keep hearts young
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Bioplastics & ... 12.8% over the next decade to reach approximately $8.9 billion by ... and forecasts for all the given segments on global as well ...
(Date:2/20/2017)... YORK , Feb. 20, 2017  This Report analyzes the ... Hardware, and Biocontent. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... Read the full report: http://www.reportlinker.com/p04707099-summary/view-report.html ... Annual estimates and forecasts are ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer diagnostics and ... Oncology™” (Crosswalk), a unique precision medicine knowledge visualization and decision support platform. ... Inspirata’s diagnostic cockpit and is downloadable as an app for any mobile device ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... catheters associated with peritoneal dialysis, announced today that it has published the result ... system in Peritoneal Dialysis International (PDI), the official Journal of the International ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
Breaking Biology News(10 mins):